PHAT: SEC Form 8-K filed by Phathom Pharmaceuticals Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for PHAT
Across the 28 sessions after earlier PHAT headlines, the stock closed higher 11 times and lower 17 times, with a median move of 2.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | PHAT | SPY |
|---|---|---|---|
| Oct 23, 2026 | Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA | -18.1% | -0.5% |
| Oct 19, 2026 | Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026 | +1.3% | +0.4% |
| Oct 12, 2026 | Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026 | -1.7% | -0.1% |
| Oct 8, 2026 | Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting | +4.7% | -0.4% |
| Sep 29, 2026 | Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD | +0.1% | -0.2% |
| Sep 9, 2026 | Leerink Partners initiated coverage on Phathom Pharmaceuticals with a new price target | -8.1% | -0.5% |
Quantisnow market dataNASDAQ
PHAT
Phathom Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2019
Get push alerts for PHAT
Full PHAT profile on Quantisnow Follow PHAT and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time